A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Advanced Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 May 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Mivebresib (Primary) ; Venetoclax (Primary)
Indications Acute myeloid leukaemia; Breast cancer; Colorectal cancer; Head and neck cancer; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer; Small cell lung cancer; Solid tumours; Uveal melanoma
Focus Adverse reactions; First in man; Pharmacokinetics
Sponsors AbbVie

02 May 2021 Results (n=44; data cutoff: 3 Dec 2019) from AML patients enrolled in dose-escalation cohort published in the Cancer
10 Dec 2019 Results (as of Jan 2019; n=44) presented at the 61st Annual Meeting and Exposition of the American Society of Hematology
16 Aug 2019 Results (n=72) of dose escalation cohort published in the Clinical Cancer Research

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com